ALA report: lung cancer survival has improved, but remains significantly lower for people of color

Cancer History Project Conversation with The Cancer Letter

Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer

On Nov. 24, 2003, an article in The Boston Globe told the story of a patient’s remarkable response to gefitinib, a drug that had recently been approved by FDA.

October 04, 2024

Vol.50 No.37

By Paul Goldberg and McKenzie Prillaman

In Brief

Scarlett Lin Gomez awarded AACR Distinguished Lectureship on the Science of Cancer Health Disparities

The American Association for Cancer Research will award Scarlett Lin Gomez with the 2024 AACR Distinguished Lectureship on the Science of Cancer Health Disparities during the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved to be held in Los Angeles Sept. 21-24.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.

September 13, 2024

Vol.50 No.34

Cancer History Project Conversation with The Cancer Letter

Lung cancer couldn’t slow down physician and athlete Lawrence Phillips

Something odd turned up in one of Lawrence Phillips’s routine health screenings in 2008.

September 06, 2024

Vol.50 No.33

By Deborah Doroshow and McKenzie Prillaman

Drugs & Targets

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

FDA granted priority review for Imfinzi (durvalumab), AstraZeneca’s supplemental Biologics License Application, based on the results from the positive ADRIATIC phase III trial in patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based concurrent chemoradiotherapy.

September 06, 2024

Vol.50 No.33

Drugs & Targets

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Daiichi Sankyo and Merck have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 targeting T-cell engager.

August 09, 2024

Vol.50 No.32

ALA report: lung cancer survival has improved, but remains significantly lower for people of color

YOU MAY BE INTERESTED IN

Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer

Scarlett Lin Gomez awarded AACR Distinguished Lectureship on the Science of Cancer Health Disparities

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

Lung cancer couldn’t slow down physician and athlete Lawrence Phillips

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login